Status:
RECRUITING
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recrui...
Detailed Description
This is a descriptive observational study, in which data are collected in an EGFR mutant NSCLC. Our research plan aims to use multi-omics approaches to predict the likelihood of patients developing br...
Eligibility Criteria
Inclusion
- Patients must be ≥18 years.
- Provision of fully informed consent prior to any study specific procedures.
- Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
- Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
- According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion
- None
Key Trial Info
Start Date :
December 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05991193
Start Date
December 29 2023
End Date
December 31 2025
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer hospital
Changsha, Hunan, China